Haisco Pharmaceutical Group Co., Ltd.

Equities

002653

CNE100001BC7

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-07-21 pm EDT 5-day change 1st Jan Change
29.48 CNY +0.92% Intraday chart for Haisco Pharmaceutical Group Co., Ltd. -1.07% +27.34%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
China Drug Regulator Accepts Haisco Pharma's Application for Injectible Pain Reliever MT
Haisco Pharmaceutical Expects to Double H1 Profit on Product Growth, Subsidies; Shares Up 4% MT
Haisco Pharmaceutical Group Gets China Nod for Diabetic Neuropathy Tablets MT
Haisco Pharmaceutical Gets Nod to Trial Tumor Drug; Shares Up 3% MT
Chinese Drug Regulator Accepts Haisco Pharma's Application for Pulmonary Disease Drug MT
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Haisco Pharmaceutical Gets Nod to Trial HSK16149 Capsules MT
Haisco Pharma Gets Nod to Trial Asthma Drug MT
Haisco Pharma Gets Nod to Trial HSK16149 Capsule as Central Neuropathic Pain Drug MT
Haisco Pharma's Unit Gets Nod to Trial Drug for Hemolytic Diseases MT
Haisco Pharma's Unit Gets Nod to Trial Tumor Drug Candidate MT
Haisco Pharma to Set Up New Subsidiary in China’s Tibet Region MT
Haisco Pharmaceutical Signs $462 Million Deal with Italy’s Chiesi Farmaceutici MT
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Haisco Pharmaceutical Group Co., Ltd. Announces Management Changes CI
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Haisco Pharmaceutical's Unit Gets Greenlight to Trial Diabetes Drug MT
Haisco Pharma's Rupatadine Fumarate Tablets Passes Regulator's Evaluation MT
Haisco Pharma’s Blood Clot Drug Passes Generic Consistency Evaluation in China MT
Haisco Pharma Unit Gets Certification for Formula Food MT
Haisco Pharma Gets Nod for HSK31679 Tablet Trial MT
Haisco Pharma Unit Registers Nutritional Formula Food MT
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Haisco Pharma Unit Gets Certificate for Two Food Supplements MT
Chart Haisco Pharmaceutical Group Co., Ltd.
More charts
Logo Haisco Pharmaceutical Group Co., Ltd.
Haisco Pharmaceutical Group Co.,Ltd., formerly Xizang Haisco Pharmaceutical Group Co., Ltd., is a China-based company principally engaged in the research, development, manufacture and sale of new drugs and high-end medical instrument. The Company’s main products are categorized into small volume injections, big volume injections, freeze-dried powder injections and others, which include polyene phosphatidylcholine injections, lipid solubility vitamins injection series, doradiazine methanesulfonate injections, nalmefene hydrochloride injections, fluprofen tromethamine tablets and cefoperazone sodium tazobactam sodium for injections, among others. The Company distributes its products in domestic market.
Employees
5,448
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
27.76CNY
Average target price
36.19CNY
Spread / Average Target
+30.37%
Consensus
  1. Stock Market
  2. Equities
  3. 002653 Stock
  4. News Haisco Pharmaceutical Group Co., Ltd.
  5. Chinese Drug Regulator Accepts Haisco Pharma's Application for Pulmonary Disease Drug